Premium
AbCellera Biologics Inc (ABCL)
NASDAQ
Hot Features
Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575,... AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.9983 | 18.5213358071 | 5.39 | 6.79 | 5.37 | 8330652 | 6.07300067 | CS |
| 4 | 1.3383 | 26.500990099 | 5.05 | 6.79 | 3.94 | 9260116 | 5.14295955 | CS |
| 12 | 2.7683 | 76.4723756906 | 3.62 | 6.79 | 3.22 | 6170278 | 4.55427743 | CS |
| 26 | 2.9083 | 83.5718390805 | 3.48 | 6.79 | 2.745 | 5046092 | 4.17004857 | CS |
| 52 | 4.0883 | 177.752173913 | 2.3 | 6.79 | 2.27 | 5429387 | 4.27094428 | CS |
| 156 | -0.4217 | -6.19236417034 | 6.81 | 8.05 | 1.8906 | 3374551 | 4.04373309 | CS |
| 260 | -19.3017 | -75.1331257299 | 25.69 | 27.4603 | 1.8906 | 2864472 | 6.41811111 | CS |
Transactions différées
Pour obtenir des transactions en temps réel, améliorez votre compte
Passer à la version en temps réel| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
